Last updated on July 2019

KRN125 for Mobilization of Hematopoietic Stem Cells


Brief description of study

Data collection to evaluate safety and effect of hematopoietic stem cell mobilization into the peripheral blood after a single subcutaneous (SC) dose of KRN125(Pegfilgrastim)in healthy adults.

Detailed Study Description

KRN125 is administered as a single SC dose to the Day 1. The stem cell mobilization protocols will be monitored for safety and efficacy during the mobilization period.

Clinical Study Identifier: NCT03993639

Find a site near you

Start Over